IgAN: Pathogenesis and pathophysiology | With Dr Richard Lafayette
IgA nephropathy (IgAN) is a leading cause of chronic kidney disease and the most common glomerular disease worldwide. But its pathogenesis has not yet been fully elucidated, leaving some questions so far unanswered. Join Dr Richard Lafayette for an overview of our current understanding of how this disease develops and presents. By completing this module you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at nephrology.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: 1. Penfold RS, Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018 Apr 12;11:137-148. 2. Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4): 677-686. doi: 10.2215/CJN.07420716 3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1–S276. 4. Chang S, Li X-K. The role of immune modulation in pathogenesis of IGA nephropathy. Front Med.7:92. Disclosures: Dr Richard Lafayette declares the following: Research: Travere, Omeros, Calliditas, Vera, Otsuka/Visterra Consulting: Travere, Omeros, Calliditas, Vera, Otsuka/Visterra All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Travere Therapeutics. The educational content has been developed by Liberum IME and validated by an independent steering committee; Travere Therapeutics has had no influence on the content of this education.